Discover the most-read SMA stories of 2025, featuring updates on the gene therapy Zolgensma, next-generation treatments, and ...

Leuprorelin acetate, a medicine approved in the U.S. for prostate cancer, may slow the progression of SMA type SBMA, ...

Columnist Connie Chandler offers a message of courage and hope for those spending this season in a hospital bed.

A new review of studies reveals that incorporating SMA into newborn screening programs yields clinical improvements and ...

This Christmas, columnist Ari Anderson gives thanks that some health complications he experienced post-surgery resolved on ...

Disability life coaching is turning out to be just the balm columnist Brianna Albers needed to recall the importance of community in SMA.

Fatigue in the diaphragm may contribute to breathing issues in people with spinal muscular atrophy, a new study reports.

Cherie Ehlert lives in Vancouver, British Columbia, Canada. She is a disability advocate and created “Charlie's Angels” to raise funds for children's healthcare services and spinal muscular atrophy, ...

FDA approved Itvisma, a one-time gene therapy for SMA patients ages 2 and older. Itvisma restores SMN protein, improving motor function and reducing treatment burden. A Novartis executive says the ...

Zolgensma improved motor function in SMA children with tracheostomies. No new safety risks were observed for SMA patients with tracheostomy who received Zolgensma. Many patients received Spinraza or ...

What is Itvisma for SMA? Itvisma (onasemnogene abeparvovec-brve) is a one-time gene therapy that’s approved for adults and children, 2 years and older, with spinal muscular atrophy (SMA). Itvisma is ...